Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases

National Medical Journal of China

Volumn 89, Issue 30, 2009, Pages 2099-2102

  Tian, Zhuang ^a   Chen, Tai Bo ^a   Fang, Quan ^a   Zeng, Xiao Feng ^a   Liu, Yong Tai ^a   Li, Meng Tao ^a   Jiang, Xiu Chun ^a   Gao, Peng ^a   Cheng, Kang An ^a   Wang, Qian ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Adenosine; Connective tissue diseases; Hypertension, pulmonary; Iloprost; Vasodilation

Indexed keywords

ADENOSINE; ANTIHYPERTENSIVE AGENT; ILOPROST; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; VASODILATATION;

ADENOSINE; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CONNECTIVE TISSUE DISEASES; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MIDDLE AGED; PROSPECTIVE STUDIES; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84871704110     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.30.006     Document Type: Article

References (13)

1. Sanchez O, Sitbon O, Jai's X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, 2006, 130: 182-189.
2. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004, 25: 2243-2278.
3. Morgan JM, McCormack DG, Griffiths MJ, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation, 1991, 84: 1145-1149.
4. Nootens M, Schrader B, Kaufmann E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest, 1995, 107: 54-57.
5. Reichenberger F, Mainwood A, Doughty N, et al. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med, 2007, 101: 217-222.
6. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J, 2005, 26: 895-902.
7. Pelleg A, Porter RS. The pharmacology of adenosine. Pharmacotherapy, 1990, 10: 157-174.
8. 2008, 18: 56-58.
9. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J, 2008, 31: 891-901.
10. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J, 2003, 24: 356-365.
11. Hoeper MM, Olschewski H, Ghofrani HA. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol, 2000, 35: 176-182.
12. Limsuwan A, Khosithseth A, Wanichkul S. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv, 2009, 73: 98-104.
13. 2008, 25: 1157-1158.